I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes mellitus (DM) is a chronic disease that necessitates continuing therapies and regular self-care. It is considered as universally prevalent and millions worldwide are living with diabetes.\[[@ref1]\] DM is a heterogeneous group of metabolic disorders characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism, and may result in chronic complications including microvascular, macrovascular, and neuropathic disorders.\[[@ref2]\] Different approaches for DM management are applied to reduce the risk for microvascular and macrovascular disease complications, to ameliorate symptoms, to reduce mortality, and to improve quality of life.\[[@ref3]\]

Glimepiride is an oral antidiabetic drug, which belongs to the sulfonylurea group and is usually used for patients with type 2 DM. Glimepiride acts to lower blood glucose by stimulating the release of insulin from pancreatic β cells\[[@ref4]\] and also by increasing the sensitivity of peripheral tissues to insulin, but the mechanism by which glimepiride lowers blood glucose during long-term administration has not been clearly established.\[[@ref5]\]

Glimepiride is chemically designed as: 3-ethyl-4-methyl-*N*-(4\[*N*-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl\]phenethyl)-2-oxo-2,5-dihydro1H-pyrrole-1-carboxamide, with a molecular formula of C~24~H~34~N~4~O~5~S and a molecular weight of 490.6 \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref6]\]

![Glimepiride chemical structure](JPBS-11-49-g001){#F1}

Nutritional status and food components may alter the pharmacokinetics or pharmacodynamics of a drug.\[[@ref7]\] The interaction between glimepiride and food components may alter its absorption,\[[@ref8]\] leading to either decreasing or increasing its plasma levels, causing failure of treatment or increasing the risk of side effects and toxicity. Glimepiride is processed in liver by cytochrome p450 (CYP450) enzyme and any drug that increase or decrease the activity of such enzyme may alter the action of glimepiride.\[[@ref9][@ref10]\]

When glimepiride was given with meals, the mean T~max~ was slightly increased (12%) and the mean *C*~max~ and area under curve (AUC) were slightly decreased by 8% and 9%, respectively.\[[@ref11]\] Also, after oral administration, glimepiride is completely (100%) absorbed from the gastrointestinal tract.\[[@ref12]\] A significant absorption of glimepiride within 1 h after administration and peak drug levels (*C*~max~) at 2--3 h was reported.\[[@ref13]\] In addition, recently, it was found that licorice juice significantly (*P* \< 0.05) increased the AUC~0--6~, *C*~max~, and t~1/2~ of glimepiride and significantly (*P* \< 0.05) decreased the clearance and elimination rate constant, whereas grapefruit juice found to have no significant (*P* \> 0.05) effect on glimepiride pharmacokinetics.\[[@ref14]\] Moreover, the risk of hypoglycemia may be increased or prolonged when moderate or large amounts of alcohol have been consumed concurrently with sulfonylurea antidiabetic agents.\[[@ref15]\]

Vimto is a soft drink that is a local favorite drink, especially during Ramadan in Arab world. It was first manufactured and registered as a health tonic in cordial form in 1908 in Manchester, England, and then decades later as a carbonated drink. It contains the juice of grapes, raspberries, and black currants (in a 3% concentration), flavored with herbs and spices and sugar. It is considered as one of the most popular drinks during the holy month of Ramadan in some Arab countries.\[[@ref16]\] Although, the Vimto drink is consumed in a limited population, we used it as an example of high-sugar content drinks that were consumed by a wide range of populations including diabetic without knowing the effect of these drinks on their medications.

Several methods were applied for the determination of glimepiride separately or in combination with other drugs in pharmaceutical formulations and biological samples, such as spectrophotometry,\[[@ref17]\] ultraviolet spectrophotometric,\[[@ref18]\] reversed-phase high-performance liquid chromatography (RP-HPLC),\[[@ref19]\] liquid chromatography--mass spectrometry (LC-MS/MS),\[[@ref12][@ref20]\] liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS),\[[@ref21]\] and recently high-performance liquid chromatography--mass spectrometry (HPLC-MS).\[[@ref14]\]

This study aimed to develop and validate a simple, rapid, and sensitive method for the determination of glimepiride in rat serum using HPLC-MS/MS. Also, to study the possible pharmacokinetic interactions between glimepiride and Vimto soft drink when they are taken together in experimental rats without studying the exact molecular mechanism resulting from the constituents that make such effect. Also, we aimed to make patients aware about their drug effects when combined with some diets or beverages.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Chemicals and reagents {#sec2-1}
----------------------

Both glimepiride (B\#WS/07/272) and clarithromycin (B\#0040310095) were obtained from the Jordanian Pharmaceutical Manufacturing, Jordan. Rats for this study were obtained from animal house in the University of Petra. Deionized water (Nanopure, Fisher Scientific), methanol and acetonitrile of advanced gradient grade (Fisher Scientific, USA), and formic acid and sodium hydroxide of advanced gradient grade (GPR Supplies Ltd, United Kingdom) were used in this study.

Instrumentation {#sec2-2}
---------------

An API mass spectrometer (HITACHY, Japan) composed of degasser (Agilent 1260), solvent delivery systems pump (Agilent 1200), autosampler (Agilent 1200), Thermostat column compartment (Waters, USA) (Agilent 1200), and API 4000 mass spectrometer, ACE 5, C18 (50 × 2.1 mm), 5 μm; computer system, Windows XP, SP3, data management software 1.5.1; sonicator, crest model-175 (Ultrasonic), Sartorius balance BP 2215, Sartorius PH meter (professional meter PP-25) (Goettingen, Germany), and centrifuge (Eppendorf 5417C) (Hamborg, Germany) were used.

Chromatographic conditions for glimepiride {#sec2-3}
------------------------------------------

A mobile phase consisting of 25% of water (0.5 mM ammonium chloride and 0.04% formic acid) and 75% of methanol. ACE C8 column particle size of 5 µm and dimensions of 50 × 2.1 mm was used. Detailed information about mass spectrometric conditions are shown in [Table 1](#T1){ref-type="table"}.

###### 

Summary of chromatographic conditions and mass spectrometric conditions

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HPLC conditions                                       Pump flow rate\   Autosampler injection volume\   Auto sampler temp.\           Column oven temp.\               
                                                       0.5 mL/min         2 μL                            12°C                          20°C                             
  ---------------------------------------------------- ------------------ ------------------------------- ----------------------------- -------------------- ----- ----- -----
  Chromatography                                       Total run time     1.0 min                                                                                        

  Mobile phase (isocratic elution)                     Step               Total time (min)                Flow rate (μL/ min)           A                    B           

  (%) 0.5 mM ammonium chloride and 0.04% formic acid   (%) Methanol                                                                                                      

  0                                                    0.00               500                             25                            75                               

  1                                                    1.00               500                             25                            75                               

  Column type                                                                                             ACE C8, (50 × 2.1) mm, 5 μm                                    

  Expected retention times (minutes)                                      Glimepiride                                                   Clarithromycin                   

                                                       0.65                                                  0.41                                                        

  MRM detection conditions                             Analytes and IS    Q1 mass                         Q3 mass                         DP                 EP    CE    CXP

  Glimepiride                                          491.198             352.200                         76                           10                   19    10    

  Clarithromycin                                       748.501             158.300                         51                           10                   39    10    

  MS conditions                                        CUR                CAD                             IS voltage                                         TEM   GC1   GC2

  Positive                                             20                   10                            5500                          400                        45    40
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAD = Collision associated dissociation gas, CE = Collision energy, CUR = Curtain gas, CXP = Collision cell exit potential, DP = Declustering potential, EP = Entrance potential, GC1 = Nebulizing gas, GC2 = Drying gas, MRM = Multiple Ion Monitoring, MS = Mas spectrometer, TEM = Temperatur, IV = Ionspray voltage

Preparation of stock and working solutions of clarithromycin (internal standard) {#sec2-4}
--------------------------------------------------------------------------------

A stock solution of clarithromycin (100 µg/mL) was prepared by dissolving 10 mg in 100 mL methanol. Working solutions of internal standard (IS) (500 ng/mL) was prepared by diluting 1.0 mL of the stock solutions in 200 mL methanol.

Preparation of stock and working solutions of glimepiride {#sec2-5}
---------------------------------------------------------

Stock solution of glimepiride (25 µg/mL) was prepared by dissolving 12.5 mg in 500 mL methanol and stored at --20°C until used. Working solutions (0.2, 0.4, 2.0, 4.0, 8.0, 16.0, 24.0, 0.6, 12.0, and 20.0 μg/mL) were prepared as in [Table 2](#T2){ref-type="table"}.

###### 

Preparation of glimepiride serial solutions and serum spiking samples

                       Serial solutions   Serum spiking                                    
  -------------------- ------------------ --------------- ------ ----- ----- ------ ------ ----
  Calibration points   1                  8               1000   0.2   C1    25     1000   5
  2                    16                 1000            0.4    C2    25    1000   10     
  3                    80                 1000            2.0    C3    25    1000   50     
  4                    160                1000            4.0    C4    25    1000   100    
  5                    320                1000            8.0    C5    25    1000   200    
  6                    640                1000            16.0   C6    25    1000   400    
  7                    960                1000            24.0   C7    25    1000   600    
  QC points            8                  24              1000   0.6   QCL   25     1000   15
  9                    480                1000            12.0   QCM   25    1000   300    
  10                   800                1000            20.0   QCH   25    1000   500    

Preparation of calibration curve and quality control samples in serum {#sec2-6}
---------------------------------------------------------------------

As in [Table 2](#T2){ref-type="table"}, seven spiked concentrations (calibration curve) (5, 10, 50, 100, 200, 400, and 600 ng/mL) and three quality control (QC) concentrations (15, 300, and 500 ng/mL) were prepared in serum. Samples were divided in Eppendorf tubes and stored at --30°C and were used daily during analysis.

Method validation {#sec2-7}
-----------------

### Precision and accuracy {#sec3-1}

The intraday precision and accuracy of the method was determined by the analysis of six replicates of the lower limit of quantification (LLOQ) and QC levels in the same day. The inter-day variability was determined by the analysis of three runs of the LLOQ and QC levels in three different days. The relative standard deviation (RSD) values or coefficient of variation (CV%) were calculated from the ratios of the standard deviation (SD) to the mean and expressed as percentage.

![](JPBS-11-49-g002.jpg)

The accuracy of the method was determined by comparing practical amounts recovered from the control samples with actual values present in the samples (theoretical values).

![](JPBS-11-49-g003.jpg)

The acceptable limits of intraday and inter-day accuracy and precision were below 15% except at the LLOQ, for which accuracy and precision should be below 20% as per the European medicines agency's scientific guidelines.

### Linearity {#sec3-2}

The calibration curve of glimepiride is a plot of the peak area ratio (PAR) of the drug to the IS as a function of the drug concentration (*C*). This gives the following equation: (PAR = Slope × *C* + Intercept).

Linearity of the plotted curve is evaluated through the value of the correlation coefficient (*R*^2^), which should be more than 0.98.

### Stability {#sec3-3}

A short-term stability, freeze--thaw stability, and autosampler stability tests were performed. Stability was carried out using low and high concentrations of QC samples. The analyte was considered stable if the assay values were within the acceptable limit of accuracy ±15%.

### Recovery {#sec3-4}

The absolute recovery was calculated by comparing the AUCs for serum extracted samples with un-extracted samples (solution), those represent 100% recovery. However, extent of the recovery of the glimepiride and IS should be consistent and reproducible.

Preclinical study {#sec2-8}
-----------------

### Preparation of glimepiride solution and Vimto juice {#sec3-5}

A total of 15 mg of glimepiride was dissolved in 1000 mL of 20 mM NaOH solution (0.015 mg/mL) (the added NaOH is required to increase the solubility of glimepiride). Vimto juice was prepared by mixing 50 mL of Vimto juice with 150 mL water.

### Animal handling and study protocol {#sec3-6}

The study protocol was approved by the ethical committee of the High Research Council, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan. Adult Sprague Dawley laboratory rats with an average weight of 200 g. Rats were placed in air-conditioned environment (20--25°C) and exposed to a photoperiod cycle (12 h light/12 h dark) daily. Rats were fasted for 24 h before experiment day.

Rats were labeled and grouped as control (*n* = 8) (glimepiride only) and test (*n* = 8) (glimepiride and Vimto) groups. Glimepiride 0.1 mg/kg was given by oral gavage to the control group. Vimto juice was pre-administered for half an hour to the second group before glimepiride dose of 0.1 mg/kg.

### Sample collection and processing {#sec3-7}

Blood samples were collected from the rat's tail at zero, 0.5, 1, 2, 3, 4, 6, 8, 10, and 24.0 h of drug administration and were immediately centrifuged at 5000 rpm for 10 min; serum obtained was placed into labeled Eppendorf tubes and stored at --30°C till analysis.

Sample extraction of the rat samples, calibrator, and QC samples was carried out by taking 100 µL of blank, zero, standards, QC low (QCL), QC mid (QCM), QC high (QCH) or rat samples in tubes and mixed with 50 µL of IS solution containing 500 ng/mL clarithromycin by vortexing for 15 s, then 600 μL of methanol was added and vortexed vigorously for 1.0 min, followed by centrifugation at 14000 rpm for 7 min. A total of 250 μL of the supernatant was transferred to flat bottom insert and then 2 μL was injected.

Pharmacokinetic analysis {#sec2-9}
------------------------

Plasma level--time profiles of glimepiride and glimepiride with Vimto juice were assembled by drawing a curve between average plasma levels (in ng/mL) and time (in hours). The parameters: area under the curve to 24 h (AUC~last~), area under the curve to infinity (AUC~inf~), maximum concentration of drug in serum (*C*~max~), time to achieve *C*~max~ (*T*~max~), half-life (*t*~0.5~), and elimination rate constant (*K*~el~) were calculated by non-compartmental analysis model using WinNonlin software, version 5.1. Tripos, L.P, St. Louis, MO, USA.

Statistical analysis {#sec2-10}
--------------------

The statistical significance of difference in the mean of the variables, such as *C*~max~, *T*~max~ and AUC~last~, between two groups was assessed using the independent samples Student's *t*-test used to identify significance in pharmacokinetic parameters using 95% confidence interval. The Statistical Package for the Social Sciences (SPSS), version 21, (SPSS Inc., Chicago, IL, USA) computer software was used, and *P* \< 0.05 was considered significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A validation process was applied for 3 days to determine glimepiride levels in rat's plasma as per international council for harmonisation (ICH) of technical requirements for pharmaceuticals for human use and the European medicines agency's scientific guidelines using LC-MS/MS method. The chromatograms of glimepiride blank, zero, and rat plasma sample after 1 h are shown in Figures [2](#F2){ref-type="fig"}--[4](#F4){ref-type="fig"}.

![Glimepiride blank chromatogram](JPBS-11-49-g004){#F2}

![Glimepiride zero chromatogram](JPBS-11-49-g005){#F3}

![Glimepiride rat unknown chromatogram at 1 h](JPBS-11-49-g006){#F4}

Precision {#sec2-11}
---------

### Intraday {#sec3-8}

The precision or coefficient of variation (CV%) of mean predicted concentrations (LLOQ, QCL, QCM, and QCH) during the 3 days of validation ranged between 1.67% and 5.45%. Detailed results are shown in [Table 3](#T3){ref-type="table"}.

###### 

Results of inter- and intraday precision and accuracy

                               LLOQ            QCL              QCM              QCH
  ---------------------------- --------------- ---------------- ---------------- ----------------
  Day 1                                                                          
   Target conc.                5 ng/mL         15 ng/mL         300 ng/mL        500 ng/mL
   Calculated conc. ± SD       4.73 ± 0.10     15.04 ± 0.52     303.10 ± 15.31   507.66 ± 25.53
   Accuracy ± SD               94.69 ± 2.08    100.30 ± 3.47    101.00 ± 5.10    101.53 ± 5.11
   CV%                         2.19            3.461            5.05             5.03
   Range                       4.95--4.87      14.51--15.86     287.34--324.32   471.51--524.35
  Day 2                                                                          
   Target conc.                5 ng/mL         15 ng/mL         300 ng/mL        500 ng/mL
   Calculated conc. ± SD       5.07 ± 0.28     15.58 ± 0.50     296.22 ± 11.65   513.68 ± 17.20
   Accuracy ± SD               101.32 ± 5.52   103.87 ± 3.36    98.74 ± 3.88     102.74 ± 3.44
   CV%                         5.45            3.23             3.93             3.35
   Range                       4.58--5.31      14.70--16.03     280.99--308.77   492.27--533.42
  Day 3                                                                          
   Target conc.                5 ng/mL         15 ng/mL         300 ng/mL        500 ng/mL
   Calculated conc. ± SD       5.09 ± 0.12     15.39 ± 0.60     308.06 ± 5.16    501.95 ± 16.31
   Accuracy ± SD               101.79 ± 3.87   102.62 ± 3.98    102.69 ± 1.72    100.39 ± 3.26
   CV%                         3.81            3.88             1.67             3.25
   Range                       4.79--5.32      14.76--16.23     299.94--312.37   482.93--521.89
  Average for the three days                                                     
   Target conc.                5 ng/mL         15 ng/mL         300 ng/mL        500 ng/mL
   Calculated conc. ± SD       4.96 ± 0.25     15.34 ± 0.59     302.46 ± 11.91   507.76 ± 19.52
   Accuracy ± SD               99.27 ± 3.97    102.60 ± 1.285   102.60 ± 4.86    101.55 ± 1.18
   CV%                         3.82            3.64             3.93             3.84

### Inter-day {#sec3-9}

Inter-day precision was evaluated over the 3 days. CV% was less than 5.12% (LLOQ). CV% for QCL, QCM, and QCH were 3.64, 3.93, and 3.84%, respectively [Table 3](#T3){ref-type="table"}.

The precision (CV %) did not exceed 20% for LLOQ and 15% for the other concentrations, which prove the closeness of the measurements.

Accuracy {#sec2-12}
--------

### Intraday {#sec3-10}

The accuracy of mean predicted concentration compared to target concentrations (LLOQ, QCL, QCM, and QCH) are shown in [Table 3](#T3){ref-type="table"}, the minimum value was 94.68% and the maximum was 104.87% during validation. Also, the mean accuracy for LLOQ and QCL was 101.79% and 102.62%, respectively.

### Inter-day {#sec3-11}

Inter-day accuracy over the concentration range was between 99.26% and 102.26% as shown in [Table 3](#T3){ref-type="table"}. Compared with the accepted criteria, which is 85%--115% for all concentrations except for LLOQ, which is 80%--120%, the accuracy obtained is within the required range according to ICH guidelines.

Linearity {#sec2-13}
---------

Linearity is determined by calculating the regression line using a mathematical treatment of the results (i.e., least mean squares) versus glimepiride concentrations. Equation of linear regression was used for estimating glimepiride levels at each validation day, using target concentration for getting the "D area/IS area" at each of the validation days and for stability testing.

During validation, the coefficient (*R*^2^) was greater than 0.99. The linearity for the mean six calibration curves and correlation, slope, *R*^2^, and intercept is shown in [Figure 5](#F5){ref-type="fig"}. Therefore, validation results of the 3 days are passed within the required criteria in terms of linearity.

![The plot of linearity for mean six calibration curves (correlation = 0.999927, slope = 0.003679, *R*^2^ = 0.999854, intercept = 0.005945)](JPBS-11-49-g007){#F5}

Stability {#sec2-14}
---------

### Autosampler stability {#sec3-12}

Autosampler stability was examined using 15 ng/mL (QCL) and 500 ng/mL (QCH) samples. Samples were injected directly at 0.00 h and reinjected after 24.0 h. Results were less than 15% \[[Table 4](#T4){ref-type="table"}\].

###### 

Glimepiride quality control samples stability at 10°C (Autosampler stability)

  Time              AUC (drug)   AUC (IS)   Ratio    Measured concentration (ng/mL)   Mean measured   Accuracy %   Stability
  ----------------- ------------ ---------- -------- -------------------------------- --------------- ------------ -----------
  QCL (15 ng/mL)                                                                                                   
  00.00 h           16,267       390,147    0.042    15.144                           15.22           100.96       102.06
  15,473            376,586      0.041      14.924   99.49                                                         
  16,626            386,703      0.043      15.615   104.10                                                        
  24.00 h           16,519       411,224    0.040    14.592                           14.20           97.28        97.97
  16,588            398,425      0.042      15.122   100.81                                                        
  15,893            383,748      0.041      15.043   100.29                                                        
  QCH (500 ng/mL)                                                                                                  
  00.00 h           16,267       390,147    0.042    15.144                           15.22           100.96       102.06
  15,473            376,586      0.041      14.924   99.49                                                         
  16,626            386,703      0.043      15.615   104.10                                                        
  24.00 h           16,519       411,224    0.040    14.592                           14.20           97.28        97.97
  16,588            398,425      0.042      15.122   100.81                                                        
  15,893            383,748      0.041      15.043   100.29                                                        

QCL = 15 ng/mL, QCH = 500 ng/mL

### Short-term stability {#sec3-13}

QCL and QCH samples were spiked and kept at room temperature for 24 h and then processed with freshly prepared QC samples \[[Table 5](#T5){ref-type="table"}\].

###### 

Glimepiride quality control samples stability at 10°C (Autosampler stability)

  Time              AUC (drug)   AUC (IS)   Ratio     Measured concentration (ng/mL)   Mean measured   Accuracy %   Stability
  ----------------- ------------ ---------- --------- -------------------------------- --------------- ------------ -----------
  QCL (15 ng/mL)                                                                                                    
   00.00 h          16,267       390,147    0.042     15.144                           15.22767        100.96       101.59
  15,473            376,586      0.041      14.924    99.49                                                         
  16,626            386,703      0.043      15.615    104.10                                                        
   24.00 h          30,816       414,042    0.074     15.325                           14.98867        102.16       98.43
  27,822            386,797      0.072      14.776    98.50                                                         
  29,194            403,593      0.072      14.865    99.10                                                         
  QCH (500 ng/mL)                                                                                                   
   00.00 h          574,571      403,533    1.424     515.925                          513.5013        103.19       102.66
  581,429           410,402      1.417      513.345   102.67                                                        
  577,878           409,580      1.411      511.234   102.25                                                        
   24.00 h          948,204      416,593    2.276     499.207                          500.1593        99.84        97.40
  936,898           415,144      2.257      494.968   98.99                                                         
  974,939           422,348      2.308      506.303   101.26                                                        

QCL = 15 ng/mL, QCH = 500 ng/mL

### Freeze and thaw stability {#sec3-14}

Three cycles of freezing and thawing of the concentrations, 15 ng/mL (QCL) and 500 ng/mL (QCH), were used. The mean stability was 97.72%--102.32%, \[[Table 6](#T6){ref-type="table"}\].

###### 

Glimepiride quality control samples freeze and thaw stability

  Time              AUC (drug)   AUC (IS)   Ratio     Measured concentration (ng/mL)   Mean measured   Accuracy %   Stability
  ----------------- ------------ ---------- --------- -------------------------------- --------------- ------------ -----------
  QCL (15 ng/mL)                                                                                                    
   00.00 h          16,267       390,147    0.042     15.144                           15.22767        100.96       101.95
  15,473            376,586      0.041      14.924    99.49                                                         
  16,626            386,703      0.043      15.615    104.10                                                        
   Cycle \#3        31,286       405,612    0.077     14.946                           14.93633        99.64        98.08
  32,532            427,029      0.076      14.760    98.40                                                         
  32,340            414,973      0.078      15.103    100.69                                                        
  QCH (500 ng/mL)                                                                                                   
   00.00 h          574571       403533     1.424     515.925                          513.5013        103.19       102.32
  581,429           410,402      1.417      513.345   102.67                                                        
  577,878           409,580      1.411      511.234   102.25                                                        
   Cycle \#3        1,071,343    420,382    2.548     499.528                          501.8187        99.91        97.72
  1,092,881         427,368      2.557      501.241   100.25                                                        
  110,1627          427,848      2.575      504.687   100.94                                                        

QCL = 15 ng/mL, QCH = 500 ng/mL

Absolute recovery {#sec2-15}
-----------------

Serum samples containing concentrations of QCL (15 ng/mL), QCM (300 ng/mL), and QCH (500 ng/mL) were prepared in triplicate. The coefficient of variation for glimepiride was between (0.37%--2.26%) in mobile phase, whereas in serum was ranged between 1.25% and 2.14% as shown in [Table 7](#T7){ref-type="table"}.

###### 

Absolute mean peak area and precision for glimepiride and internal standard per quality control level in mobile phase and serum

  Concentration    AUC (drug)   AUC (IS)   Mean (drug)   CV% (drug)   Mean (IS)   CV% (IS)
  ---------------- ------------ ---------- ------------- ------------ ----------- ----------
  Mobile phase                                                                    
   15 ng/mL QCL    12,395       420,368    12,526        1.70         420,263     0.42
  12,771           421,975                                                        
  12,412           418,446                                                        
   300 ng/mL QCM   263,349      422,043    256,675       2.26         424,373     0.83
  252,856          422,656                                                        
  253,819          428,419                                                        
   500 ng/mL QCH   415,490      423,249    417,262       0.37         425,134     0.51
  418,067          427,520                                                        
  418,229          424,632                                                        
  Serum                                                                           
   15 ng/mL QCL    12,152       412,926    12,281        1.70         407,857     1.08
  12,521           405,152                                                        
  12,169           405,493                                                        
   300 ng/mL QCM   257,185      415,511    250,975       2.14         416,127     1.00
  247,898          420,564                                                        
  247,842          412,305                                                        
   500 ng/mL QCH   417,223      406,114    411,479       1.25         414,423     1.76
  407,343          419,700                                                        
  409,870          417,454                                                        

The absolute recovery for glimepiride was ranged from 97.78% to 98.61% and for IS were ranged from 97.05% to 98.06 \[[Table 8](#T8){ref-type="table"}\].

###### 

Absolute recovery of glimepiride and internal standard

  Concentration     Glimepiride   Internal standard                               
  ----------------- ------------- ------------------- ------- --------- --------- -------
  15 ng/mL (QCL)    12,281        12,526              98.04   407,857   420,263   97.05
  300 ng/mL (QCM)   250,975       256,675             97.78   416,127   424,373   98.06
  500 ng/mL (QCH)   411,479       417,262             98.61   414,423   425,134   97.48

Effect of pre-administration of Vimto on glimepiride pharmacokinetics {#sec2-16}
---------------------------------------------------------------------

As shown in [Figure 6](#F6){ref-type="fig"}, glimepiride concentrations were lower after concomitant administration with Vimto. The maximum serum concentration (*C*~max~) (without Vimto) was 126.01 ng/mL after an hour of administration and the minimum concentration was 7.63 ng/mL after 24 h. In addition, glimepiride after drinking Vimto reached its maximum concentration of 57.87 ng/mL after 2 h and decreased gradually to a minimum concentration of 5.63 ng/mL after 24 h \[[Table 9](#T9){ref-type="table"}\].

![Glimepiride concentration--time profile. Data shown as mean ± standard deviation (SD) (*n* = 8)](JPBS-11-49-g008){#F6}

###### 

Serum glimepiride drug concentration at selected time after oral dose of glimepiride and glimepiride in the presence of Vimto

  Time (hour)   Concentration ± STD (ng/mL) Glimepiride   Concentration ± STD (ng/mL) Glimepiride + Vimto   *P* values
  ------------- ----------------------------------------- ------------------------------------------------- ------------
  0.0           0.00                                      0.00                                              
  0.5           120.05 ± 73.20                            52.41 ± 33.55                                     0.032
  1.0           126.01 ± 64.17                            57.05 ± 28.89                                     0.015
  2.0           119.50 ± 51.71                            57.87 ± 22.59                                     0.008
  3.0           102.69 ± 47.69                            54.32 ± 21.55                                     0.020
  4.0           70.68 ± 36.85                             45.00 ± 12.76                                     0.084
  6.0           41.66 ± 10.93                             35.40 ± 6.71                                      0.189
  8.0           42.24 ± 13.36                             32.86 ± 6.17                                      0.093
  10.0          32.59 ± 7.67                              30.16 ± 5.98                                      0.491
  24.0          7.63 ± 3.15                               5.63 ± 0.84                                       0.150

STD = standard deviation

Also, pharmacokinetic parameters for both groups were compared as in [Table 10](#T10){ref-type="table"}. Both *C*~max~ and AUC (126.01 ng/mL and 964.70 ng^\*^h/mL) were significantly (*P* \< 0.05) reduced (57.87 ng/mL and 665.91 ng^\*^h/mL).

###### 

Comparison in major pharmacokinetic parameters between glimepiride alone and glimepiride with Vimto

  Parameter    Glimepiride   Glimepiride + Vimto   *P* value
  ------------ ------------- --------------------- -----------
  AUC~0--24~   964.70        665.91                0.039
  *T*~max~     1.00          2.00                  0.109
  *C*~max~     126.01        57.87                 0.016
  *Kel*        0.106         0.114                 0.350
  Half-life    6.55          6.09                  0.284

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Validated analytical method of glimepiride was developed to evaluate the consistency of measuring the drug level in rat plasma.

Drug--food relations may alter the pharmacokinetics or pharmacodynamics of a drug or nutritional constituent or nutritional status.\[[@ref7]\] Nutrients may activate or suppress some enzymes in the gut, which will affect the bioavailability of certain drugs. The interaction between drugs and nutrients may cause elevation of drug concentration in plasma, which increases the risk of side effects and toxicity, or decrease in plasma levels of drug, which may lead to failure of treatment. Also, nutrients and ingredients in beverages may increase or decrease the bioavailability of the drug.\[[@ref14][@ref22]\]

Glimepiride is metabolized by CYP450 and it is a substrate for p-GP OATP2B1 transporter in human.\[[@ref23]\] The lower pharmacokinetics values of glimepiride when administered with Vimto may be due to the induction of the CYP450 enzyme by the components of Vimto. This is in accordance with the results of McCall\[[@ref11]\] who revealed lower *C*~max~ and AUC when drug taken after a meal. On contrast, in a previous work of our group, we showed that licorice juice elevated the bioavailability of the glimepiride, whereas grape juice showed no significant effect.\[[@ref14]\] The mechanism behind the decrease in glimepiride bioavailability may be due to the induction of metabolic enzymes required for its metabolism. Lower glimepiride concentrations affect its hypoglycemic effect. For that, physicians should advise the patients with diabetes to take care of the food they consume when they take glimepiride.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

A simple, rapid, and sensitive method for validation and determination of glimepiride in the presence of Vimto juice has been developed by using HPLC-MS/MS. Serum glimepiride level was affected by the concomitant administration of Vimto.

Glimepiride reaches its maximum serum level within 1 h, *C*~max~ for glimepiride alone is 126.01 ng/mL, *C*~max~ for glimepiride with Vimto is 57.87 ng/mL, the difference between *C*~max~ (single administration vs. combination with Vimto) is significant, and the difference in AUC is significant as well (*P* \< 0.05). The difference between *C*~max~ (single administration vs. combination with Vimto) is significant and the difference in AUC is significant (*P* \< 0.05).

This study can lead to many possible future studies such as studying the effect of this combination on human serum.
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